ACE — Ascelia Pharma AB Income Statement
0.000.00%
Last trade - 00:00- SEK290.61m
- SEK240.75m
Annual income statement for Ascelia Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 93.4 | 138 | 147 | 111 | 67.8 |
| Operating Profit | -93.4 | -138 | -147 | -111 | -67.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -99.7 | -130 | -133 | -110 | -80.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -98.7 | -126 | -131 | -109 | -80 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -98.7 | -126 | -131 | -109 | -80 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -98.7 | -126 | -131 | -109 | -80 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.6 | -2.64 | -2.61 | -2.24 | -1.48 |
| Dividends per Share |